Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.53 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29026490 | 1.00 | SMPD1 (0.62) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL29026432 | 1.00 | SMPD1 (0.62) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL29026469 | 1.00 | SMPD1 (0.62) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL29026512 | 1.00 | SMPD1 (0.62) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL21291922 | 1.00 | SMPD1 (0.62) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL2049378 | 0.93 | SMPD1 (0.56) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL21291944 | 0.89 | SMPD1 (0.49) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL2379992 | 0.85 | SMPD1 (0.43) | SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL2048023 | 0.85 | SMPD1 (0.50) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL21291940 | 0.84 | SMPD1 (0.51) | SMPD1LPAR3LPAR1LPAR2LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051325-B | Spirothiocyclobutane nucleosides | 詹森药业有限公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| EP-3676276-A1 | SPIROTHIETANE NUCLEOSIDES | Janssen Pharmaceutica NV (BE) | 2020-07-08 | — | — | EP | disclosed |
| CN-111051325-A | Spirothiacyclobutanenucleosides | 詹森药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019043177-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | WO | disclosed |
| US-8017135-B1 | Lipid-drug conjugates for local therapy of eye diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-13 | — | — | US | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | SMPD1 343/4885LPAR3 2076/4885LPAR1 1954/4885 |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | SMPD1 478/4885LPAR3 2937/4885LPAR1 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.